Exploratory meta-analysis on dose-related efficacy and complications of rhBMP-2 in anterior cervical discectomy and fusion: 1,539,021 cases from 2003 to 2017 studies

Ya-Dan Wen,Wei-Min Jiang,Hui-Lin Yang,Jin-Hui Shi
DOI: https://doi.org/10.1016/j.jot.2020.01.002
IF: 6.6
2020-09-01
Journal of Orthopaedic Translation
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Anterior cervical discectomy and fusion (ACDF), commonly using autogenous iliac bone graft, may be limited by donor site availability, donor site morbidity, lower fusion rate among specific patients and longer surgical time. Surgeons used rhBMP-2 as an alternative to fill these clinical needs. However, studies comparing ACDF with and without rhBMP-2 have reported conflicting results on efficacy and complications.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>To evaluate efficacy and complications through dose-related rhBMP-2 and surgical level-dependence in ACDF.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Evidence acquisition</h3><p>We comprehensively searched PubMed and the Cochrane Library and performed a systematic review and cumulative meta-analysis of all randomised controlled trials (RCTs), prospective and retrospective comparative studies assessing with and without rhBMP-2 treatments.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Evidence synthesis</h3><p>A total of 1,539,021 cases including 1 RCT, 4 prospective studies and 24 retrospective studies were identified. Patients in ACDF with rhBMP-2 might benefit from significantly higher fusion rates than those in ACDF with non-rhBMP-2, not only total value but also in three tiers of rhBMP-2 doses. It is worth noting that the low dose of rhBMP-2 (&lt;0.7 mg/level) showed highest fusion rate among all rhBMP-2 doses. Patients in rhBMP-2 also experienced a higher complication rate, dysphagia and wound infections than those in non-rhBMP-2. In 2-level ACDF, the fusion rate was significantly better in rhBMP-2 than in non-rhBMP-2 but not for complication rate. Surgery operative time, lengths of hospital stay and neurologic symptoms did not differ significantly between two treatments.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>rhBMP-2 chosen in ACDF offered not only higher fusion, but also higher complication rate with more dysphagia and wound infections than non-rhBMP-2. To gain the efficacy and safety, rhBMP-2 dosing recommendations for ACDF would be better &lt;0.7 mg/ level. Moreover, rhBMP-2 may be an option to improve nonunion in high risk of multi-level ACDF.</p>
orthopedics
What problem does this paper attempt to address?